Celgene’s Otezla OK’d in plaque psoriasis

The FDA on 23 September gave Celgene the go-ahead to market Otezla (apremilast), a selective inhibitor of phosphodiesterase 4 (PDE4), to treat moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate.

The FDA on 23 September gave Celgene the go-ahead to market Otezla (apremilast), a selective inhibitor of phosphodiesterase 4 (PDE4), to treat moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate.

The drug is the first and only PDE4 inhibitor approved in plaque psoriasis, a chronic inflammatory disease of the skin,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Dermatological

More from Therapeutic Category